SeNostic Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

SeNostic General Information

Description

Operator of a diagnostics company intended to provide a precise and accurate early differential diagnosis of multiple neurodegenerative disorders. The company provides biochemicals for neuroscience research and develops Vitro diagnostic tests for neurodegenerative disorders as well as provides an innovative way to amplify and characterize disease-specific protein aggregates present in tissues and body fluids, enabling patients to avail themselves of proper treatment for their disease.

Contact Information

Website
www.senostic.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Feodor-Lynen-Strasse 21
  • 30625 Hannover
  • Germany
+49 0511 00000000
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Drug Discovery
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Feodor-Lynen-Strasse 21
  • 30625 Hannover
  • Germany
+49 0511 00000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SeNostic Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 29-May-2019 Completed Generating Revenue
2. Seed Round 25-Jan-2016 Completed Generating Revenue
1. Seed Round Completed Startup
To view SeNostic’s complete valuation and funding history, request access »

SeNostic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a diagnostics company intended to provide a precise and accurate early differential diagnosis of multiple ne
Biotechnology
Hannover, Germany
11 As of 2023
0000000000 0

000000

a pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
0000 000000000
New York, NY
00 As of 0000
00000
0000000000 0 00000

000000

x ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate veli
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SeNostic Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Volastra Venture Capital-Backed New York, NY 00 00000 0000000000 0 00000
Avalyn Pharma Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
Ona Therapeutics Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
G1 Therapeutics Formerly VC-backed Durham, NC 000 00000 000000&0 00000
Lung Therapeutics Formerly VC-backed Austin, TX 00 000.00 000000&0 000.00
You’re viewing 5 of 7 competitors. Get the full list »

SeNostic Patents

  • 7

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 6

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

SeNostic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2781104-T3 Procedure for the diagnosis of neurodegenerative diseases Active 01-Jul-2014 00000000000
EP-2963421-A1 Process for diagnosis of neurodegenerative diseases Inactive 01-Jul-2014 00000000000 0
EP-3164716-B1 Process for diagnosis of neurodegenerative diseases Active 01-Jul-2014 00000000000
EP-3164716-A1 Process for diagnosis of neurodegenerative diseases Active 01-Jul-2014 00000000000
ES-2652609-T3 Method for prion production and analysis Active 16-Feb-2011 C07K14/47
To view SeNostic’s complete patent history, request access »

SeNostic Executive Team (8)

Name Title Board Seat
Thomas Strehl Chief Executive Officer
Jörg Bode Managing Director, Chief Operating Officer & Chief Financial Officer
Arne Ungruh Managing Director
Ingo Schlößin-Beneke Managing Director
Joachim Glaubitz Chief Scientific Officer
You’re viewing 5 of 8 executive team members. Get the full list »

SeNostic Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SeNostic Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
NBank Capital Venture Capital Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg Venture Capital Minority 000 0000 000000 0
To view SeNostic’s complete investors history, request access »

Ready to get started?

Request a free trial

SeNostic FAQs

  • When was SeNostic founded?

    SeNostic was founded in 2014.

  • Who is the founder of SeNostic?

    Thorsten Lührs Ph.D and Christiane Ritter Ph.D are the founders of SeNostic.

  • Who is the CEO of SeNostic?

    Thomas Strehl is the CEO of SeNostic.

  • Where is SeNostic headquartered?

    SeNostic is headquartered in Hannover, Germany.

  • What is the size of SeNostic?

    SeNostic has 11 total employees.

  • What industry is SeNostic in?

    SeNostic’s primary industry is Biotechnology.

  • Is SeNostic a private or public company?

    SeNostic is a Private company.

  • What is SeNostic’s current revenue?

    The current revenue for SeNostic is 00000.

  • Who are SeNostic’s investors?

    NBank Capital, High-Tech Gründerfonds, and MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg have invested in SeNostic.

  • Who are SeNostic’s competitors?

    Volastra, Avalyn Pharma, Ona Therapeutics, G1 Therapeutics, and Lung Therapeutics are some of the 7 competitors of SeNostic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »